IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
Final subject received last dose of Ampligen (rintatolimod) in Ph 2 DURIPANC trial of Ampligen + Imfinzi for the treatment of metastatic pancreatic cancer August 5, 2026
Strong Enrollment Momentum Reported in Ph 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer August 5, 2026
First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell NHL July 28, 2026
Enrollment completed in Ph 1 Dose Escalation Study of IPH4502 in patients with advanced solid tumors July 28, 2026
Last Patient, Last Visit in LAM561 Ph 2b/3 Trial for Newly Diagnosed GBM Patients Announced July 28, 2026
Enrollment completed in Ph 2 trial of spevatamig + chemo for the 1L metastatic pancreatic ductal adenocarcinoma July 28, 2026
First Patient Dosed in Ph 1 Trial of IM-3050 in Patients with FAP-Expressing Advanced Solid Tumors July 22, 2026
Patient Treatment Restarted in Ph 2 INVINCIBLE-4 Study of Neoadjuvant INT230-6 in TNBC Patients July 21, 2026
FDA Registration-Enabling Ph 3 Confirmatory Study of Multikine® launched in Newly Diagnosed Head and Neck Cancer July 15, 2026
Ph 3 AURORA Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced NSCLC Patients with Inadequate Response to Immune Checkpoint Inhibitors initiated July 7, 2026
Independent DMC recommended continuation of Ph 3 OVATION 3 trial of IMNN-001 + SOC neoadjuvant and adjuvant chemo in 1L ovarian cancer June 30, 2026
First patient dosed in RASolute 305 Ph 3 Trial of Zoldonrasib-Chemo combo in 1L RAS G12D Metastatic Pancreatic Cancer June 30, 2026
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib June 30, 2026
First Patient enrolled in Ph 1/2 Trial Evaluating PM54 Plus Pembrolizumab in Advanced Solid Tumors June 30, 2026
Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities Announced June 30, 2026
